Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
DICE Therapeutics, Inc. DICE
$36.93
+$0.19 (0.52%)
На 18:04, 12 мая 2023
+62.47%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1839460244.00000000
-
week52high
45.99
-
week52low
12.64
-
Revenue
0
-
P/E TTM
-21
-
Beta
0.00000000
-
EPS
-2.13000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мар 2023 г. в 20:05
Описание компании
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 18 июл 2022 г. | |
| B of A Securities | Buy | 11 окт 2021 г. | |
| Cantor Fitzgerald | Overweight | 14 сент 2022 г. | |
| Stifel | Buy | 07 сент 2022 г. | |
| SVB Leerink | Outperform | Outperform | 11 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 окт 2022 г. |
| Guggenheim | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Robertson Scott M. | A | 18750 | 18750 | 27 янв 2023 г. |
| Robertson Scott M. | A | 112500 | 112500 | 27 янв 2023 г. |
| Timothy Lu | A | 15000 | 15000 | 27 янв 2023 г. |
| Timothy Lu | A | 90000 | 90000 | 27 янв 2023 г. |
| Judice Kevin | A | 50000 | 50000 | 27 янв 2023 г. |
| Judice Kevin | A | 300000 | 300000 | 27 янв 2023 г. |
| Jacobsen John R. | A | 15000 | 15000 | 27 янв 2023 г. |
| Jacobsen John R. | A | 90000 | 90000 | 27 янв 2023 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 6848911 | 1640000 | 17 окт 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 21250 | 21250 | 07 июн 2022 г. |
Новостная лента
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
04 янв 2023 г. в 16:05
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
Zacks Investment Research
02 янв 2023 г. в 11:17
Here is how DICE Therapeutics, Inc. (DICE) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
16 дек 2022 г. в 11:18
Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
30 ноя 2022 г. в 11:17
Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.
The Motley Fool
18 ноя 2022 г. в 05:52
The good times could keep on rolling for these big winners.